Status:
NOT_YET_RECRUITING
Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life
Lead Sponsor:
Jules Bordet Institute
Conditions:
Hypotestosteronism
Palliative Care
Eligibility:
MALE
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This is a monocentric, single-arm prospective pilot study that will enrol hypogonadal (testosterone \< 231 ng/dL) male subjects in best supportive care, with no further therapeutic options and no need...
Eligibility Criteria
Inclusion
- Male hypogonadal with total testosterone \< 231 ng/dl in best supportive care with no further therapeutic options and who do not wish to be reanimated.
- Age ≥ 18 years old
- Patient able to understand the patient information sheet and able to sign the Informed Consent form (ICF) prior to any study related procedure.
Exclusion
- Untreated prostate cancer, given the risk of epiduritis.
- Known hypersensitivity reactions to the study drug or to any excipients.
- Known allergies to peanuts or soya.
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07143279
Start Date
January 1 2026
End Date
November 1 2027
Last Update
January 7 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium, 1070